+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Crohn's Disease Therapeutics Market by Therapy Class, Route of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Crohn's Disease Therapeutics Market by Therapy Class, Route of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Crohn's Disease Therapeutics Market by Therapy Class, Route of Administration, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 191 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6014389
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Crohn's Disease Therapeutics Market grew from USD 13.36 billion in 2024 to USD 14.13 billion in 2025. It is expected to continue growing at a CAGR of 5.62%, reaching USD 18.55 billion by 2030.

Setting the Stage for the Future of Crohn’s Disease Therapies

Crohn’s disease remains one of the most challenging chronic inflammatory disorders, affecting millions of individuals worldwide with life-altering gastrointestinal complications. Advances in immunology and molecular biology have driven an explosion of novel therapeutic modalities, yet significant gaps remain in achieving long-term remission and minimizing adverse effects. Healthcare stakeholders are navigating a shifting terrain of regulatory approvals, payer scrutiny, and patient expectations. In this environment, a clear strategic vision grounded in robust market insights is essential for identifying unmet needs and prioritizing high-value investments.

This report offers a comprehensive executive summary of key market dynamics shaping the future of Crohn’s disease therapeutics. It synthesizes the most recent clinical breakthroughs, policy developments, and commercial trends to empower decision-makers across biopharma, payers, and provider networks. By focusing on pivotal shifts rather than incremental updates, this analysis distills actionable intelligence that will inform your strategic planning and support your efforts to deliver transformative therapies.

Redefining Treatment Pathways with Next-Generation Innovations

Over the past several years, the therapeutic landscape for Crohn’s disease has undergone a profound metamorphosis driven by breakthroughs in targeted immunomodulation and personalized medicine. Next-generation biologics targeting key inflammatory pathways have demonstrated meaningful improvements in clinical remission rates, while oral small molecules are offering patients convenient, at-home dosing options. These shifts have reshaped treatment algorithms, prompting physicians to consider earlier intervention with high-potency agents.

Concurrently, real-world evidence and digital health platforms are charting new territories for patient monitoring and adherence management. Wearable sensors, telemedicine, and mobile applications now provide clinicians with granular, longitudinal data on disease activity, enabling dynamic therapy adjustments. Payers are increasingly open to value-based contracting that ties reimbursement to patient outcomes rather than product volume. This alignment of clinical innovation, technological enablement, and payer flexibility marks a seismic shift poised to redefine long-term disease management and commercial models alike.

Navigating the Ripple Effects of 2025 US Tariff Adjustments

The implementation of new tariff measures in the United States commencing in 2025 has introduced fresh variables into global supply chains for active pharmaceutical ingredients and finished dosage forms. Raw materials originating from key export hubs now face incremental duties, increasing the cost base for both novel and established therapies. To mitigate margin erosion, manufacturers are reevaluating their sourcing strategies, exploring regional manufacturing hubs in Asia and Latin America, and negotiating volume-based concessions with API suppliers.

These tariff adjustments also have downstream implications for pricing negotiations with managed care organizations and government payers. Organizations with diversified production footprints and backward integration capabilities are best positioned to absorb or offset additional duties, while those reliant on centralized manufacturing face pressure on gross margins. In response, industry leaders are intensifying investment in supply chain transparency initiatives, enabling real-time visibility into cost fluctuations and ensuring continuity of supply in the face of evolving trade policies.

Unveiling Market Dynamics through Multifaceted Segmentation Analysis

An in-depth segmentation analysis reveals the multi-layered complexities shaping product mix and channel strategy. Within therapy classes, the biologics segment dominates through a spectrum of targeted therapies: integrin inhibitors led by vedolizumab address gut-specific pathways, interleukin-targeting agents such as risankizumab and ustekinumab modulate key immune drivers, and tumor necrosis factor blockers including adalimumab, certolizumab, and infliximab remain foundational in moderate-to-severe cases. Meanwhile, immunosuppressants anchored by methotrexate and thiopurines-most notably azathioprine and mercaptopurine-continue to serve as adjunctive options, particularly for steroid-sparing regimens. Small molecule therapies focused on Janus kinase inhibition, exemplified by tofacitinib and upadacitinib, are rapidly gaining traction for their oral administration advantages.

Route of administration further delineates market behavior: intravenous infusions facilitate controlled delivery within hospital settings, oral formulations support patient autonomy at home, and subcutaneous injections offer a hybrid model of convenience and clinical oversight. Distribution across hospital pharmacies, retail outlets, and specialty clinics influences procurement cycles, margin structures, and patient access points. Finally, end-user dynamics differentiate home care environments from institutional hospitals and dedicated specialty clinics, shaping patient support programs, nursing services, and adherence monitoring protocols. This holistic segmentation framework underpins targeted go-to-market strategies and optimizes resource allocation across stakeholder touchpoints.

Regional Nuances Shaping Global Market Trajectories

Regional heterogeneity in regulatory frameworks, reimbursement policies, and healthcare infrastructure profoundly influences therapeutic uptake and commercial strategy. In the Americas, robust payer networks, high biologic penetration, and an increasing focus on outcome-based agreements define the competitive landscape, with the United States leading in innovation adoption. Latin American markets exhibit price sensitivity and decentralized procurement, presenting both affordability challenges and opportunities for biosimilar expansion.

Across Europe, Middle East and Africa, the regulatory mosaic spans stringent centralized approvals in the European Union to emerging frameworks in the Gulf Cooperation Council and Sub-Saharan Africa. Price negotiations at national levels and co-payment structures shape formulary access, while the growing biosimilar ecosystem in Europe introduces cost-effective alternatives. In Asia-Pacific, rapid economic growth and expanding health insurance coverage fuel demand, yet variable regulatory maturity and government price controls necessitate adaptive pricing strategies. Local manufacturing partnerships often serve as gateways to market entry, balancing cost efficiencies with regulatory alignment.

Illuminating Competitive Strategies of Leading Life Science Innovators

Leading pharmaceutical innovators are deploying multifaceted strategies to strengthen their positions and expand market share. Global leaders with established biologic franchises have invested heavily in next-generation antibody constructs and subcutaneous delivery platforms to extend product lifecycles. At the same time, pioneers in small molecule research are leveraging structure-based drug design to enhance selectivity and safety profiles, differentiating their JAK inhibitors in a crowded field.

Strategic collaborations between large biotech and niche specialty firms are accelerating pipeline development, with co-development agreements focused on bispecific antibodies and novel cellular therapies. Biosimilar entrants are forging alliances with regional distributors to capitalize on cost-conscious markets, while contract manufacturers are scaling capacity to meet rising demand for both originators and follow-on products. Companies with robust real-world evidence capabilities are translating longitudinal patient data into compelling value narratives for payers, reinforcing differentiated positioning in reimbursement discussions.

Strategic Imperatives to Capitalize on Emerging Opportunities

Industry leaders must adopt a proactive stance to harness emerging opportunities and mitigate risks. Designing a diversified portfolio that spans high-value biologics, cost-effective small molecules, and next-wave precision modalities will balance revenue streams across market segments. Engaging early with payers to develop outcome-based contracting frameworks will solidify reimbursement pathways and align product value with patient benefit. Strengthening supply chain resilience through regional manufacturing partnerships and API diversification is essential to counter evolving tariff landscapes and geopolitical uncertainties.

Investing in digital health ecosystems that integrate patient-reported outcomes, adherence monitoring, and telehealth capabilities will elevate product offerings and drive real-world data generation. Cultivating strategic alliances with academic centers and technology providers can expedite clinical development and unlock novel mechanisms of action. Finally, embedding sustainability and patient equity considerations into commercial planning will resonate with regulatory authorities and payer stakeholders, positioning organizations as responsible innovators in a competitive environment.

Robust Methodology Underpinning Insightful Market Analysis

This analysis is grounded in a robust mixed-methodology approach combining primary and secondary research. Primary insights were obtained through in-depth interviews with key opinion leaders spanning gastroenterology, immunology, health economics, and payer organizations. Secondary research encompassed a systematic review of peer-reviewed publications, regulatory filings, clinical trial registries, and company disclosures. Market segmentation parameters were defined through data triangulation, ensuring consistency across therapy classes, administration routes, distribution channels, and end-user profiles.

Quantitative data inputs were validated via cross-referencing against regional sales reports, industry databases, and governmental statistics. Qualitative findings were subjected to peer review by subject matter experts to confirm interpretive accuracy and relevance. All data sources and assumptions are transparently documented in the full report, providing a replicable framework for scenario analysis and strategic planning.

Synthesis of Critical Insights Driving Informed Decision Making

The Crohn’s disease therapeutics landscape is marked by rapid innovation, evolving commercial paradigms, and differentiated patient needs. Biologics continue to lead with targeted immune modulation, while oral small molecules catalyze patient-centric treatment models. Trade policy adjustments in 2025 will influence supply chain dynamics and pricing strategies, underscoring the need for agile sourcing and manufacturing frameworks. Detailed segmentation analysis highlights the critical interplay of therapy class, administration route, channel strategy, and end-user context, informing optimized go-to-market roadmaps.

Regional insights reveal diverse regulatory and reimbursement ecosystems that require tailored strategic approaches, from value-based contracting in North America to biosimilar expansion in Europe and adaptive pricing in Asia-Pacific. Competitive intelligence underscores the importance of collaborative innovation, real-world evidence generation, and digital health integration to sustain differentiation. Collectively, these findings offer a strategic blueprint for stakeholders seeking to advance therapeutic breakthroughs and deliver meaningful outcomes for patients living with Crohn’s disease.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Therapy Class
    • Biologics
      • Integrin Inhibitors
        • Vedolizumab
      • Interleukin Inhibitors
        • Risankizumab
        • Ustekinumab
      • TNF Inhibitors
        • Adalimumab
        • Certolizumab
        • Infliximab
    • Immunosuppressants
      • Methotrexate
      • Thiopurines
        • Azathioprine
        • Mercaptopurine
    • Small Molecules
      • JAK Inhibitors
        • Tofacitinib
        • Upadacitinib
  • Route Of Administration
    • Intravenous
    • Oral
    • Subcutaneous
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Specialty Clinics
  • End User
    • Home Care Settings
    • Hospitals
    • Specialty Clinics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • AbbVie Inc.
  • Janssen Biotech, Inc.
  • Takeda Pharmaceutical Company Limited
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Merck & Co., Inc.
  • UCB S.A.
  • Celltrion, Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Crohn's Disease Therapeutics Market, by Therapy Class
8.1. Introduction
8.2. Biologics
8.2.1. Integrin Inhibitors
8.2.1.1. Vedolizumab
8.2.2. Interleukin Inhibitors
8.2.2.1. Risankizumab
8.2.2.2. Ustekinumab
8.2.3. TNF Inhibitors
8.2.3.1. Adalimumab
8.2.3.2. Certolizumab
8.2.3.3. Infliximab
8.3. Immunosuppressants
8.3.1. Methotrexate
8.3.2. Thiopurines
8.3.2.1. Azathioprine
8.3.2.2. Mercaptopurine
8.4. Small Molecules
8.4.1. JAK Inhibitors
8.4.1.1. Tofacitinib
8.4.1.2. Upadacitinib
9. Crohn's Disease Therapeutics Market, by Route of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
10. Crohn's Disease Therapeutics Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Retail Pharmacies
10.4. Specialty Clinics
11. Crohn's Disease Therapeutics Market, by End User
11.1. Introduction
11.2. Home Care Settings
11.3. Hospitals
11.4. Specialty Clinics
12. Americas Crohn's Disease Therapeutics Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Crohn's Disease Therapeutics Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Crohn's Disease Therapeutics Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. AbbVie Inc.
15.3.2. Janssen Biotech, Inc.
15.3.3. Takeda Pharmaceutical Company Limited
15.3.4. F. Hoffmann-La Roche Ltd
15.3.5. Pfizer Inc.
15.3.6. Merck & Co., Inc.
15.3.7. UCB S.A.
15.3.8. Celltrion, Inc.
15.3.9. Samsung Bioepis Co., Ltd.
15.3.10. Sandoz International GmbH
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. CROHN'S DISEASE THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. CROHN'S DISEASE THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. CROHN'S DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. CROHN'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. CROHN'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CROHN'S DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY VEDOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RISANKIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY USTEKINUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CERTOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MERCAPTOPURINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TOFACITINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY UPADACITINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 72. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 73. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 74. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 75. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 76. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 77. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 78. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2030 (USD MILLION)
TABLE 79. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 80. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 81. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 85. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 86. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 87. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 88. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 89. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 90. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2030 (USD MILLION)
TABLE 91. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 92. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 93. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 134. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 135. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 136. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 137. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 146. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 147. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 148. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 149. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 150. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 151. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2030 (USD MILLION)
TABLE 152. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 153. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 154. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 158. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 159. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 160. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 161. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 162. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 163. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2030 (USD MILLION)
TABLE 164. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 165. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 166. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 170. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 171. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 172. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 173. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 174. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 175. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2030 (USD MILLION)
TABLE 176. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 177. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 178. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 182. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 183. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 184. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 185. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 186. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 187. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2030 (USD MILLION)
TABLE 188. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 189. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 190. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 191. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. SPAIN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 194. SPAIN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 195. SPAIN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 196. SPAIN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 197. SPAIN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 198. SPAIN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 199. SPAIN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2030 (USD MILLION)
TABLE 200. SPAIN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 201. SPAIN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 202. SPAIN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. SPAIN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. SPAIN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. UNITED ARAB EMIRATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 206. UNITED ARAB EMIRATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 207. UNITED ARAB EMIRATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 208. UNITED ARAB EMIRATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 209. UNITED ARAB EMIRATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 210. UNITED ARAB EMIRATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 211. UNITED ARAB EMIRATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2030 (USD MILLION)
TABLE 212. UNITED ARAB EMIRATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 218. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 219. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 220. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 221. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 222. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 223. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2030 (USD MILLION)
TABLE 224. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 225. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 226. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 228. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. SOUTH AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 230. SOUTH AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 231. SOUTH AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 232. SOUTH AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 233. SOUTH AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 234. SOUTH AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2030 (USD MILLION)
TABLE 236. SOUTH AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 242. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 243. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 244. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 245. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 246. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 247. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2030 (USD MILLION)
TABLE 248. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 249. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 250. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 251. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 254. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 255. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 256. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 257. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 258. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 266. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 267. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 268. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 269. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 270. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 271. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2030 (USD MILLION)
TABLE 272. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 273. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 274. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 275. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 276. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 277. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 278. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 279. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 280. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 281. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 282. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 283. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2030 (USD MILLION)
TABLE 284. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 285. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 286. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 287. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 288. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 289. SWEDEN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 290. SWEDEN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 291. SWEDEN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 292. SWEDEN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 293. SWEDEN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 294. SWEDEN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 295. SWEDEN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2030 (USD MILLION)
TABLE 296. SWEDEN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 297. SWEDEN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 298. SWEDEN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 299. SWEDEN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 300. SWEDEN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 301. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 302. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 303. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 304. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 305. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (US

Companies Mentioned

The companies profiled in this Crohn's Disease Therapeutics market report include:
  • AbbVie Inc.
  • Janssen Biotech, Inc.
  • Takeda Pharmaceutical Company Limited
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Merck & Co., Inc.
  • UCB S.A.
  • Celltrion, Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages191
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 14.13 Billion
Forecasted Market Value ( USD ) by 2030 $ 18.55 Billion
Compound Annual Growth Rate5.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Crohn's Disease Therapeutics Market Size, Share & Trends Analysis Report By Type, By Route of Administration (Injectable, Oral), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Crohn's Disease Therapeutics Market Size, Share & Trends Analysis Report By Type, By Route of Administration (Injectable, Oral), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
Crohn's Disease - Pipeline Insight, 2025 - Product Image

Crohn's Disease - Pipeline Insight, 2025

  • Clinical Trials
  • 240 Pages
  • Global
From
Crohns Disease - Pipeline Insight, 2025 - Product Image

Crohns Disease - Pipeline Insight, 2025

  • Drug Pipelines
  • 100 Pages
  • Global
From
Crohn's Disease (CD) Treatment Market Report 2025 - Product Image

Crohn's Disease (CD) Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Crohn Disease Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Crohn Disease Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 81 Pages
  • Global
From

About the Crohn Disease Drug Market

Crohn Disease is a chronic inflammatory disorder of the gastrointestinal tract, and is one of the most common immune disorders. Treatment for Crohn Disease typically involves a combination of medications, lifestyle changes, and in some cases, surgery. Common medications used to treat Crohn Disease include corticosteroids, immunomodulators, biologic therapies, and antibiotics. Corticosteroids are used to reduce inflammation, while immunomodulators are used to suppress the immune system. Biologic therapies are used to target specific proteins in the body that are involved in the inflammatory process, and antibiotics are used to treat bacterial infections. The Crohn Disease Drug market is a rapidly growing segment of the Immune Disorders Drugs market. It is driven by the increasing prevalence of Crohn Disease, as well as the development of new and innovative treatments. Companies in the market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Pfizer, and UCB. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.